30 Search Results

q=Collaboration

Search Again


Shreeram Akilesh , MD, PhD

Email: shreeram@uw.edu

Phone: (206) 598-6408

Dr. Akilesh is presently applying next generation genomic tools and analyses to understand the development, structure and function of the kidney and its component cells in health and disease.

View Bio

Brittany Barber , MD, MSc, FRCSC

Email: bbarber1@uw.edu

Dr. Barber's clinical interests include head and neck cancer surgery, robotic surgery, and salivary and endocrine surgery. She has a special interest in reconstructive surgery for skin cancers. Her research interests include quality improvement in free flap reconstruction, peripheral nerve regeneration, cancer genomics, and HPV-related oropharyngeal cancer treatment.

View Bio

Kevin Barry , PhD

Email: kbarry@fredhutch.org

Phone: (206) 667-7811

Dr. Barry aims to determine how innate immune cells recognize cancer and regulate immune responses. He previously identified a novel set of immune cells that regulate immune responses that protect patients from melanoma. The number of these cells in a patient’s tumor can identify those patients who will benefit the most from immunotherapy. Dr. Barry and his team are learning more about the signals that control this set of innate immune cells in cancer. His goal is to generate novel therapies to increase cancer-killing immune responses and save lives from cancer.

View Bio

Susan Bullman , PhD

Email: sbullman@fredhutch.org

Phone: (206) 667-3449

The Bullman Lab focuses firstly on understanding the translational impact of the tumor microbiota in human cancers, and secondly on the delineation of specific mechanisms involved in the pathogenesis of microbe-associated human cancers. They combine molecular microbiology, computational biology, biochemistry, and genetics to understand host-microbial interactions within the tumor microenvironment. Through such efforts, her lab seeks to make discoveries that have both a scientific and clinical impact in the emerging area of bacterial-associated malignancies. Bacterial agents that have a role in cancer initiation or progression provide a viable route for prevention and treatment of these cancers.

View Bio

Victor Chow , MD

Email: vchow@fredhutch.org

Phone: (206) 667-7731

Dr. Chow conducts clinical research in lymphoma utilizing combination approaches with cellular-based therapies.

View Bio

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Cole DeForest , PhD

Email: ProfCole@uw.edu

Phone: (206) 543-5961

The DeForest Group seeks to integrate the governing principles of rational design with fundamental concepts from material science, synthetic chemistry, and stem cell biology to conceptualize, create, and exploit next-generation materials to address a variety of health-related problems. They are currently interested in the development of new classes of user-programmable hydrogels whose biochemical and biophysical properties can be tuned in time and space over a variety of scales. Their work relies heavily on the utilization of cytocompatible bioorthogonal chemistries, several of which can be initiated with light and thereby confined to specific sub-volumes of a sample. By recapitulating the dynamic nature of the native tissue through 4D control of the material properties, these synthetic environments are utilized to probe and better understand basic cell function as well as to engineer complex heterogeneous tissue.

View Bio

Meghan Flanagan , MD, MPH

Email: mrf22@uw.edu

Phone: (206) 667-6736

Dr. Flanagan's research areas include lymph node evaluation, patient satisfaction and chemoprevention among women at high risk of developing breast cancer. She is also interested in exploring how to improve cancer-related outcomes and access to health services.

View Bio

Jordan Gauthier , MD, MSc

Email: jgauthier@fredhutch.org

Phone: (206) 667-2713

Much of Dr. Gauthier's research has been focused on improving outcomes for patients treated with BMT or CAR T-cell therapy. Through his work, he has identified factors that can help predict the success of CAR T-cell therapy for patients who have leukemia and lymphoma.

View Bio

Taran Gujral , PhD, Msc

Email: tgujral@fredhutch.org

Phone: (206) 667-4149

Cells respond to external stimuli by activating nonlinear and highly interconnected networks of signaling proteins. Dr. Gujral's work focuses on understanding how these networks are wired in different cell types and how they influence response to growth factors or cytotoxic agents using both hypothesis driven and systems-based data-driven approaches. His lab combines approaches from molecular genetics with cell and systems biology to study a recently discovered Wnt5-Fzd2 signaling pathway in metastasis as well as cell-to-cell contact in regulating cell fate decisions.

View Bio

Heather Gustafson , PhD

Email: heather.gustafson@seattlechildrens.org

Phone: (206) 884-7339

Dr. Gustafson's career has focused on harnessing existing and developing novel technology platforms that alter macrophage function through environmental manipulation. Her current research, involves engineering several macrophage phenotype targeting methods in order to understand these interactions. Her lab does this through the development of technology platforms that target specific macrophage phenotypes and alter macrophage phenotypes for therapeutic and diagnostic applications. Through the development and use of these technologies they can develop and understanding of how environmental cues impact macrophage function, how macrophage function drives disease progression and how to harness that information to engineer novel technologies to treat disease.

View Bio

Michael Haffner , MD, PhD

Email: mhaffner@fredhutch.org

Dr. Haffner’s lab focuses on elucidating alterations of the cytoskeleton in solid tumors with a focus on prostate cancer. For instance, they have recently described a novel protein, named AIM1 that regulates cytoskeletal organization by binding to actin, a major component of the cytoskeleton. When AIM1 is present, the cells' scaffolding keeps it rigid and correct shape. When AIM1 is lost, cells can remodel their cytoskeleton more frequently, change their shape and become capable of invading and migrating to distant locations. Notably, AIM1 function is disrupted in many solid tumors and genomic alterations of AIM1 are associated with aggressive tumor growth. The goal of these studies is to understand the mechanisms that govern changes in cell architecture to explore such cancer specific changes for therapeutic targeting.

View Bio

Evan Hall , MD, MPhil

Email: evanh@seattlecca.org

Phone: (206) 606-2496

Dr. Hall's research focuses on how to measure and improve quality of life for patients with cancer. His other areas of interest include physician-patient communication, the health economics of cancer and the benefits of novel modes of patient and caregiver social support, such as online communities.

View Bio

Jared Harwood , MD, MBA

Email: harwoodj@uw.edu

Phone: (206) 221-4469

Dr. Harwood specializes in the evaluation and treatment of bone and soft tissue tumors of the extremities and pelvis and is well versed in general Orthopaedic care. His clinical interests include limb-sparing tumor resections and reconstructions, percutaneous osseointegrated prostheses, targeted muscle re-innervation, prophylactic treatment of metastatic disease, and revision joint replacement. His research interests include efficiency and sustainability of healthcare, opioid stewardship, process improvement, mentorship/leadership, communication, and outcomes in the treatment of metastatic disease.

View Bio

George Ioannou , B.M.B.Ch, MS, FAASLD

Email: George.Ioannou@va.gov

Dr. Ioannou's clinical and research interests include liver cancer, hepatitis C, non-alcoholic fatty liver disease, iron deficiency and iron overload.

View Bio

Yawen Li , PhD

Email: liyw@uw.edu

Phone: (206) 616-8518

Dr. Li is interested in therapeutic and diagnostic radiopharmaceuticals, astatine labeling reagents for small molecule labeling, and developing chemical methods for separation of high specific activity medical radionuclides.

View Bio

Ryan Lynch , MD

Email: rclynch@uw.edu

Phone: (206) 606-1739

Dr. Lynch conducts clinical trials to optimize treatments and bring novel therapeutic agents to the clinic for patients with lymphomas and chronic lymphocytic leukemia.

View Bio

Viswam Nair , MD, MS

Email: vnair@fredhutch.org

Phone: (206) 667-4971

Dr. Viswam Nair translates fundamental scientific discoveries into the clinic to improve the care of people with lung cancer. His research focuses on biomarkers, or telltale biological markers of health or disease. He studies how to best integrate molecular and imaging-based biomarkers into clinical practice to improve lung cancer detection and treatment.

View Bio

Kayode Ojo , PhD

Email: ojo67kk@uw.edu

Phone: (206) 543-0821

The research focus of the Ojo Lab is to develop novel, robust, safe and affordable antimicrobial agents that can withstand the threat of resistance while effectively treating debilitating parasitic diseases. They also have compounds in their drug library that could have an effect on breast, lung, melanoma and prostate cancer cells.

View Bio